Zenas BioPharma (ZBIO) Equity Average (2023 - 2026)

Zenas BioPharma's Equity Average history runs 4 years deep, the most recent figure standing at $289.0 million for Q1 2026.

• In Q1 2026, Equity Average fell 3.15% year-over-year to $289.0 million; the TTM figure through Mar 2026 stood at $289.0 million (down 3.15% YoY), while the FY2025 annual figure was $277.3 million, up 539.41% from the prior year.
• Equity Average was $289.0 million for Q1 2026 at Zenas BioPharma, up from $219.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $335.9 million in Q4 2024 to a low of -$270.6 million in Q2 2024.
• Historically, Equity Average has averaged $93.4 million across 4 years, with a median of $218.7 million in 2025.
• Biggest YoY gain for Equity Average was 517.18% in 2025; the steepest drop was 34.73% in 2025.
• A 4-year view of Equity Average shows it stood at -$214.0 million in 2023, then jumped by 257.0% to $335.9 million in 2024, then tumbled by 34.73% to $219.3 million in 2025, then surged by 31.79% to $289.0 million in 2026.
• The last three Equity Average figures came in at $289.0 million (Q1 2026), $219.3 million (Q4 2025), and $218.0 million (Q3 2025), per Business Quant data.